Navigation Links
Genome of CHO-K1 provides new insights into optimization of biopharmaceutical protein production
Date:8/1/2011

August 1st, 2011, Shenzhen, China and San Diego, CA BGI, the world's largest genomics organization, and GT Life Sciences, Inc., a privately held biotechnology company that utilizes a proven metabolic modeling and experimental platform to drive the discovery and design of new products and processes for the life sciences field, announced today that their collaborative study on the genomic sequence of the Chinese hamster ovary (CHO) K1 cell line was published online in Nature Biotechnology. The CHO-K1 genome is the first published cell line genome decoded by de novo sequencing and assembly. The study yields a better understanding of the genetics of CHO cells and will accelerate the discovery and development of new recombinant protein therapies.

Chinese hamster ovary (CHO) cell lines are mammalian cells derived from the ovary of the Chinese hamster and are the preferred and most commonly used mammalian hosts today in biological and medical research. These cell lines play an important role in bioprocessing research and the development of therapeutic biopharmaceuticals. Currently the worldwide market for recombinant therapeutic proteins totals more than 99 billion USD in annual revenue from a broad range of products, including monoclonal antibodies, growth factors, hormones, and blood factors.

"Recognizing the importance of CHO cell lines, we and our partners jointly initiated a study of the genome sequence of CHO-K1 cells," said co-leading author of the study Xun Xu, Vice President of Research and Development at BGI and CEO BGI Americas. "The genome sequence and comprehensive annotation of the CHO-K1 cell line provides a useful and powerful tool for scientists in biomedical areas to optimize the production process and improve the yield of therapeutic proteins," he added.

GT Life Sciences' established business platform for metabolic modeling and engineering of mammalian cells has already proven effective in optimizing CHO cell medi
'/>"/>

Contact: Jia Liu
liujia@genomics.cn
342-874-8918
Beijing Genomics Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Dissecting the genomes of crop plants to improve breeding potential
2. Genome-wide study reveals 3 new susceptibility loci for adult asthma in Japanese population
3. Mitochondrial genome mutates when reprogrammed
4. BGI develops new strategy to uncover structural variations of human genomes
5. BGI and National Wolfberry Engineering Research Center launch Chinese wolfberry genome project
6. The first studies utilizing the Collaborative Cross mice are published in Genome Research
7. BGI contributes whole genome sequencing and bioinformatics expertise to potato genome research
8. Simple little spud helps scientists crack potatos mighty genome
9. UW-Madison scientists played role in potato genome project
10. First whole-genome lung cancer study by TGen and Virginia G. Piper Cancer Center set for conference
11. Genome analysis will reveal how bacteria in our guts make themselves at home
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/24/2015)... , June 24, 2015 The biologics safety ... major drivers for the market include growth of the ... new drug launches. Over the years, the number of ... 2001 and 2010, the FDA approved 225 drug applications ... WIPO, Europe accounted for 3,822 ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... from the Wildlife Conservation Society, have announced that yellow fever ... in northeastern Argentina, a finding that underscores the importance of ... health of people and wild nature are so closely linked. ... American Journal of Primatology focuses on yellow fever outbreaks that ...
... Recent petitions from several African nations to ,downlist, the ... adequate monitoring of the impact of ivory sales or ... published today by an international group of researchers including ... sale of stockpiled ivory from South Africa, Botswana, Namibia ...
... first time, researchers have been able to confine and study ... photosynthesis, without having to pin it down so tightly as ... application to proteins of a recently developed technique, two Stanford ... behavior of the molecule for more than one second, a ...
Cached Biology News:Yellow fever strikes monkey populations in South America 2Boost ivory trade monitoring and enforcement before allowing one-off sales: UBC researcher 2Behavior of single protein observed in unprecedented detail by Stanford chemists 2Behavior of single protein observed in unprecedented detail by Stanford chemists 3
(Date:7/30/2015)... Mass. , July 30, 2015   ... solutions for the interpretation and analysis of genomic ... Matthew Fischer has joined the company as ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... capabilities to integrate, interpret, analyze and explore complex ...
(Date:7/30/2015)... , July 30, 2015 ... by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, ... & Development, Preclinical, Clinical Trial), by End Users - ... Market is expected to reach USD 2,107.99 million by ... CAGR of 15.29%. Browse more than ...
(Date:7/30/2015)...   Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... results for the second quarter 2015. ... on track to achieve our commercial and financial goals," ... the Company. "Since our last quarterly earnings report, our ...
(Date:7/30/2015)... HIGHLIGHTS:Q2 2015 Results (all changes are against ... were $697 million compared to $701 million in the ... and changes in foreign currency exchange rates decreased sales ... , By business unit, organic sales growth was 6% ... Commercial. , Reported diluted EPS was $0.98 compared ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20
... GREENWOOD VILLAGE, Colo., Dec. 22, 2011 Ampio Pharmaceuticals, ... or the "Company"), a company that discovers and develops ... entities ("NMEs"), today announced notification of the granting of ... METHOD OF USING DIKETOPIPERAZINES AND COMPOSITION CONTAINING THEM". ...
... Mich., Dec. 22, 2011  Neogen Corporation (NASDAQ: NEOG ... of FY 2012, which ended Nov. 30, increased 2.2% from ... the quarter was $5,237,000, or $0.22 per share, compared to ... $0.26 per share. Year-to-date revenues for the first ...
... 2011 Epitomics, Inc., a California based biotech ... a Star Program in collaboration with the University ... application of a new, advanced antibody assay technique, ... measurements of antibody-antigen interactions. Over the course of ...
Cached Biology Technology:Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™ 2Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™ 3Neogen Reports Second Quarter Results 2Neogen Reports Second Quarter Results 3Neogen Reports Second Quarter Results 4Neogen Reports Second Quarter Results 5Neogen Reports Second Quarter Results 6Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions 2
... CAST Equine EIA Principle: ... LTD4 and LTE4 are products ... 5-lipoxygenase and glutathione-S-transferase. In the ... "Slow Reacting Substances of Anaphylaxis ...
... contain the basic components and protocol ... ELISA plates for quantitation of a ... cell culture supernate. Every Screening Set ... Standard (5 individual standards), Streptavidin-HRP, TMB ...
... degradation is critical to the maintenance ... regulatory proteins as important and diverse ... heat shock and stress response, antigen ... and ion channels, cell cycle regulation, ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
Biology Products: